Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,755,094
  • Shares Outstanding, K 156,882
  • Annual Sales, $ 1,094 M
  • Annual Income, $ -139,310 K
  • 60-Month Beta 1.83
  • Price/Sales 4.98
  • Price/Cash Flow 56.16
  • Price/Book 4.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.39
  • Number of Estimates 3
  • High Estimate -0.27
  • Low Estimate -0.48
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -95.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.28 +3.50%
on 04/25/19
37.75 -19.71%
on 04/09/19
-3.07 (-9.20%)
since 03/25/19
3-Month
29.28 +3.50%
on 04/25/19
37.75 -19.71%
on 04/09/19
-3.76 (-11.04%)
since 01/25/19
52-Week
27.54 +10.06%
on 12/26/18
51.70 -41.37%
on 06/19/18
-13.76 (-31.22%)
since 04/25/18

Most Recent Stories

More News
GILD vs. ALKS: Which Stock Is the Better Value Option?

GILD vs. ALKS: Which Stock Is the Better Value Option?

GILD : 64.14 (+2.13%)
ALKS : 30.31 (-12.78%)
Alkermes Plc Reports First Quarter 2019 Financial Results

-- First Quarter Revenues of $223.1 Million, Primarily Driven by ~8% Year-Over-Year Growth of Proprietary Product Net Sales --

ALKS : 30.31 (-12.78%)
Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing

Alkermes plc (Nasdaq: ALKS) today announced that C. Todd Nichols, an executive with more than two decades of extensive commercial experience in the biopharmaceutical sector, will become the company's Senior...

ALKS : 30.31 (-12.78%)
Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, Apr. 25, 2019, to discuss the company's first quarter 2019 financial results....

ALKS : 30.31 (-12.78%)
Market Trends Toward New Normal in Granite Construction, Alkermes plc, Rexford Industrial Realty, Ultra Clean, Stellus Capital Investment, and Astronics -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Granite Construction Incorporated...

GVA : 43.48 (-6.55%)
UCTT : 11.86 (-3.73%)
REXR : 37.16 (unch)
SCM : 14.43 (+0.07%)
ALKS : 30.31 (-12.78%)
ATRO : 32.97 (-0.15%)
Alkermes Reports Positive Data From Schizophrenia Study

Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.

AZN : 39.06 (+0.88%)
JNJ : 139.65 (+0.32%)
AGN : 141.49 (+1.31%)
ALKS : 30.31 (-12.78%)
Alkermes Plc Shares Up 2.9% Since SmarTrend's Buy Recommendation (ALKS)

SmarTrend identified an Uptrend for Alkermes Plc (NASDAQ:ALKS) on March 19th, 2019 at $35.09. In approximately 3 weeks, Alkermes Plc has returned 2.88% as of today's recent price of $36.10.

ALKS : 30.31 (-12.78%)
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ALPINE (Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness), a first-of-its-kind, six-month study evaluating...

ALKS : 30.31 (-12.78%)
Alkermes Announces Departure of Jim Robinson

Alkermes plc (Nasdaq: ALKS) announced today that Jim Robinson, President and Chief Operating Officer, has resigned from his position and will leave the company, effective April 19, 2019, for personal reasons....

ALKS : 30.31 (-12.78%)
Watch for Alkermes Plc to Potentially Pullback After Gaining 3.40% Yesterday

Alkermes Plc (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $36.65 to a high of $37.14. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $36.45...

ALKS : 30.31 (-12.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

See More Share

Trade ALKS with:

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Key Turning Points

2nd Resistance Point 35.14
1st Resistance Point 32.72
Last Price 30.31
1st Support Level 28.59
2nd Support Level 26.87

See More

52-Week High 51.70
Fibonacci 61.8% 42.47
Fibonacci 50% 39.62
Fibonacci 38.2% 36.77
Last Price 30.31
52-Week Low 27.54

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar